You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《复牌公告》中国医疗集团(08225.HK)向药监局申请恢复利托那韦生产
阿思达克 01-30 08:12

中国医疗集团(08225.HK)公布,旗下新型冠状病毒肺炎临床特别专案组研究发现利托那韦(Ritonavir)对新型冠状病毒(2019-nCoV)有抑制作用和疗效报告,中国科学院武汉病毒研究所等也发现其在细胞层面上对新型冠状病毒(2019-nCoV)有较好抑制作用。

目前集团关联公司万全万特厦门有限公司是一家唯一国内历史生产过该产品制剂,企业同时拥有原料批文,申请相关专利和已经向国家药监局申请重新恢复生产。集团将负责进一步临床研究和申报工作。

集团疫情临床特别行动组组还在继续昼夜从上千个可能治疗的新老药品中通过临床大数据进行筛选。

公司董事局注意到昨日(29日)股份之成交价及成交量异常变动。经合理查询後,董事局确认并不知悉导致价格或成交量变动的任何原因,或任何必须公告以避免公司证券出现虚假市场的资料,或须予披露的任何内幕消息。

该公司已申请股份於今早起复牌。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account